Bioaffinity Technologies revenue was $6.16M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $1.6M, up 10.1% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, BIAF annual revenue was $6.2M, with -34.2% growth year-over-year.
BIAF past revenue growth
How has BIAF's revenue growth performed historically?
Bioaffinity Technologies (NASDAQ: BIAF) reported Q4 2025 revenue of $1.59 million up 27.85% year over year. In the same quarter last year, Bioaffinity Technologies's revenue was $2.21 million.
What was Bioaffinity Technologies's revenue in 2025?
Bioaffinity Technologies's annual revenue for the twelve months ending Dec 31, 2025 was $6.16 million, a 34.18% decrease year over year.
How much does Bioaffinity Technologies make in a day?
Based on Bioaffinity Technologies annual revenue for the past five years, BIAF makes an average of $9,896.59 per day.
What was Bioaffinity Technologies's annual revenue growth in the past year?
As of Q2 2026, Bioaffinity Technologies's revenue has grown -34.18% year over year. This is 42.84 percentage points lower than the US Diagnostics & Research industry revenue growth rate of 8.66%. Bioaffinity Technologies's revenue in the past year totaled $6.16 million.
How much does Bioaffinity Technologies make in a year?
Bioaffinity Technologies's revenue by year for the past five years is:
Bioaffinity Technologies's revenue for the twelve months ending Dec 31, 2025 was $6.16 million, a 34.18% decrease year over year.
Bioaffinity Technologies's annual revenue for Dec 31, 2024 was $9.36 million, a 269.68% increase from 2023.
Bioaffinity Technologies's annual revenue for 2023 was $2.53 million, a 52,627.44% increase from 2022.
Bioaffinity Technologies's annual revenue for 2022 was $4.80 thousand, a Infinity% increase from 2021.
Bioaffinity Technologies's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.